

Reimbursement Rate Updates for Procedure Code Q5107 Effective January 1, 2020

Information posted March 16, 2020

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, pre-certification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.

Effective March 12, 2020, for dates of service on or after January 1, 2020, the reimbursement rate for procedure code Q5107 Mvasi (Bevacizumab) will be updated.

The following table shows the updates:

TOS*	Procedure Code	Age Range	Non-Facility (N)/Facility (F)	Current Medicaid Fee	Percent Reduction	Current Adjusted Medicaid Fee	Medicaid Fee Effective 1/1/2020	Percent Reduction	Adjusted Medicaid Fee Effective 1/1/2020
1 (Medical Services)	Q5107	0-999	N/F	Not a Benefit	0.00%	Not a Benefit	\$69.77	0.00%	\$69.77

Affected claims with dates of service from January 1, 2020, through March 12, 2020, if any are identified, will be reprocessed. Providers are not required to appeal the claims unless they are denied for additional reasons after the claims reprocessing is completed.

For more information, call the TMHP Contact Center at 800-925-9126.